Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study.

[1]  A. Kastrati,et al.  Randomized, Double-Blind, Placebo-Controlled Trial of Oral Sirolimus for Restenosis Prevention in Patients With In-Stent Restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) Trial , 2004, Circulation.

[2]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[3]  R. Virmani,et al.  Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial). , 2003, The Journal of invasive cardiology.

[4]  D. Burkhoff,et al.  Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy , 2003, Circulation.

[5]  P. Serruys,et al.  Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. , 2003, Journal of the American College of Cardiology.

[6]  P. Teirstein,et al.  Pilot Trial of Oral Rapamycin for Recalcitrant Restenosis , 2003, Circulation.

[7]  P. Serruys,et al.  Two-Year Angiographic and Intravascular Ultrasound Follow-Up After Implantation of Sirolimus-Eluting Stents in Human Coronary Arteries , 2003, Circulation.

[8]  Patrick W Serruys,et al.  Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. , 2003, Journal of the American College of Cardiology.

[9]  Antonio Colombo,et al.  Mechanism of Late In-Stent Restenosis After Implantation of a Paclitaxel Derivate–Eluting Polymer Stent System in Humans , 2002, Circulation.

[10]  R. Virmani,et al.  Oral Everolimus Inhibits In-Stent Neointimal Growth , 2002, Circulation.

[11]  P. Serruys,et al.  Angiographic Findings of the Multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): Sirolimus-Eluting Stents Inhibit Restenosis Irrespective of the Vessel Size , 2002, Circulation.

[12]  P. Serruys,et al.  Persistent Inhibition of Neointimal Hyperplasia After Sirolimus-Eluting Stent Implantation: Long-Term (Up to 2 Years) Clinical, Angiographic, and Intravascular Ultrasound Follow-Up , 2002, Circulation.

[13]  P. Serruys,et al.  Intravascular Ultrasound Findings in the Multicenter, Randomized, Double-Blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) Trial , 2002, Circulation.

[14]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[15]  C. Di Mario,et al.  First Clinical Experience With a Paclitaxel Derivate–Eluting Polymer Stent System Implantation for In-Stent Restenosis: Immediate and Long-Term Clinical and Angiographic Outcome , 2002, Circulation.

[16]  Benno J. Rensing,et al.  Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up , 2001, Circulation.

[17]  R. Poston,et al.  Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. , 1999, Circulation.

[18]  S Marx,et al.  Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. , 1999, Circulation.

[19]  R. Calne,et al.  Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. , 1999, Transplantation.

[20]  J. Badimón,et al.  Rapamycin inhibits vascular smooth muscle cell migration. , 1996, The Journal of clinical investigation.

[21]  J. Slaton,et al.  Potential Applications of Therapeutic Drug Monitoring of Sirolimus Immunosuppression in Clinical Renal Transplantation , 1995, Therapeutic drug monitoring.

[22]  S. Marx,et al.  Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. , 1995, Circulation research.

[23]  A. Matas,et al.  Prolongation Of Renal Allograft Survival In A Large Animal Model By Oral Rapamycin Monotherapy , 1995, Transplantation.

[24]  K. Shirabe,et al.  Rapamycin in a Porcine Renal Transplant Model , 1993, Transplantation proceedings.

[25]  P. Friend,et al.  Rapamycin in experimental renal allografts in primates. , 1991, Transplantation proceedings.

[26]  R. Morris,et al.  Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. , 1991, Transplantation proceedings.

[27]  S. Thiru,et al.  Rapamycin in experimental renal allografts in dogs and pigs. , 1990, Transplantation proceedings.